Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Multiple Myeloma 4Renal Insufficiency 2Paraproteinemias 2Neoplasms, Plasma Cell 2Neoplasms by Histologic Type 2Neoplasms 2Hematologic Diseases 2Blood Protein Disorders 2Monoclonal Gammopathy of Undetermined Significance 1Immunoglobulin Light-chain Amyloidosis 1Cryoglobulinemia, Familial Mixed 1Amyloidosis 1

Interventions

Dexamethasone 3isatuximab 2Lenalidomide 2pomalidomide 1daratumumab 1Ranitidine 1Diphenhydramine 1Cyclophosphamide 1Bortezomib 1Acetaminophen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Paraproteinemias × isatuximab × Clear all
NCT05147493 2022-03-29

A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment

Hellenic Society of Hematology

Phase 2 Unknown
51 enrolled
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

NCT05298683 2022-03-28

A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

Hellenic Society of Hematology

Phase 2 Unknown
108 enrolled
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡